Ewa Lupa Laskus, MD
Pulmonary Disease · Scottsdale, AZNPI 1811960602
Payments from drug & device makers
Across 162 payments — averaging $23.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Insmed, Inc.$564
- GSK$443
- United Therapeutics Corporation$393
- Sanofi$314
- Boehringer Ingelheim$251
- Intuitive Surgical$225
- plus $2K from 28 others
What the payments were for
- Food & beverage$3,56595%
- Education$2035%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Insmed, Inc. | 22 | $564 |
| GSK | 19 | $443 |
| United Therapeutics Corporation | 14 | $393 |
| Sanofi | 9 | $314 |
| Boehringer Ingelheim | 12 | $251 |
| Intuitive Surgical | 1 | $225 |
| AstraZeneca | 15 | $210 |
| Actelion Pharmaceuticals US, Inc. | 5 | $147 |
| Jazz Pharmaceuticals Inc. | 6 | $132 |
| Mylan Specialty L.p. | 5 | $117 |
| Amgen | 6 | $108 |
| Merck | 5 | $88 |
| Regeneron Healthcare Solutions, Inc. | 3 | $86 |
| Electromed, Inc. | 9 | $83 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $78 |
| Grifols USA, LLC | 3 | $59 |
| CSL Behring | 2 | $51 |
| Baxter Healthcare | 1 | $43 |
| Covis Pharma GmbH | 1 | $36 |
| Gilead | 2 | $33 |
| Viiv Healthcare Company | 2 | $32 |
| Verona Pharma, Inc. | 1 | $31 |
| Mayne Pharma Commercial LLC | 2 | $29 |
| Paratek Pharmaceuticals, Inc. | 2 | $23 |
| Advanced Respiratory, Inc | 2 | $23 |
| Novartis | 1 | $23 |
| Vifor Pharma, Inc. | 1 | $22 |
| CMP Pharma, Inc. | 1 | $21 |
| Viatris Specialty LLC | 1 | $19 |
| Teva Pharmaceuticals USA, Inc. | 1 | $19 |
| Avadel CNS Pharmaceuticals, LLC | 1 | $17 |
| Pfizer | 1 | $16 |
| Pulmonx Corporation | 1 | $16 |
| Philips North America LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$225
- DUPIXENT$120
How this compares
$3,767 in reported general payments places this provider in the 55th percentile of 250 pulmonary disease providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 271 | $196,901 |
| NucalaMepolizumab | 13 | $143,864 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 117 | $93,549 |
| Breo ElliptaFluticasone/Vilanterol | 114 | $67,708 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 107 | $56,282 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 62 | $43,627 |
| Arnuity ElliptaFluticasone Furoate | 129 | $37,452 |
| Spiriva RespimatTiotropium Bromide | 39 | $27,970 |
| Advair HfaFluticasone Propion/Salmeterol | 47 | $22,936 |
| XareltoRivaroxaban | 18 | $17,236 |
| EliquisApixaban | 18 | $14,246 |
| Incruse ElliptaUmeclidinium Bromide | 32 | $14,031 |
| SymbicortBudesonide/Formoterol Fumarate | 48 | $13,394 |
| Bevespi AerosphereGlycopyrrolate/Formoterol Fum | 17 | $9,969 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 57 | $8,854 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Nucala, Breo Ellipta, Anoro Ellipta, Arnuity Ellipta | $443 | $516,238666 claims |
| AstraZenecaBreztri Aerosphere, Symbicort, Bevespi Aerosphere | $210 | $116,912182 claims |
| Boehringer IngelheimStiolto Respimat, Spiriva Respimat | $251 | $71,597101 claims |
| PfizerEliquis | $16 | $14,24618 claims |
| MerckDulera | $88 | $5,69015 claims |
| Covis Pharma GmbHAlvesco | $36 | $3,73514 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 250 pulmonary disease providers in Arizona.
Other pulmonary disease in Scottsdale
- Omar MohamedalyScottsdale$223K
- Karen SwansonScottsdale$173K
- Umesh GoswamiScottsdale$39K
- Suchitra PilliScottsdale$38K
- Yasemin TashmanScottsdale$21K
- Laszlo VaszarScottsdale$18K
- Muhammad SalimChandler$5.9M
- Vikas SayalBullhead City$3.7M
- David BaratzPhoenix$2.2M
- James RossPhoenix$2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.